Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Kymera Therapeutics (NASDAQ:KYMR) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
3
0
0
0
Last 30D
0
1
0
0
0
1M Ago
0
0
0
0
0
2M Ago
2
2
0
0
0
3M Ago
0
0
0
0
0
Analysts have set 12-month price targets for Kymera Therapeutics, revealing an average target of $53.0, a high estimate of $56.00, and a low estimate of $47.00. Observing a 42.28% increase, the current average has risen from the previous average price target of $37.25.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we gain insights into how financial experts perceive Kymera Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Jeff Jones
Oppenheimer
Announces
Outperform
$53.00
-
Srikripa Devarakonda
Truist Securities
Raises
Buy
$54.00
$41.00
Edward Tenthoff
Piper Sandler
Raises
Overweight
$56.00
$39.00
Eric Joseph
JP Morgan
Raises
Overweight
$47.00
$34.00
Bradley Canino
Stifel
Raises
Buy
$55.00
$35.00
Key Insights:
Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Kymera Therapeutics. This information provides ...Full story available on Benzinga.com
Related tickers: KYMR.
Read Full Article